Clinical Trials Browser

Salivary Gland Neoplasms × sacituzumab govitecan × 90 days × Clear all

NCT05884320 2026-03-20

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

Phase 2 Recruiting

Salivary Gland Neoplasms